multimmune Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Financing Rounds
  • 3

multimmune General Information

Description

Developer of pharmaceutical products intended for cancer patients. The company's proprietary technological platform helps in the detection of cell surface-bound heat shock protein 70, Hsp 70, which forms a large proportion of cancer cells but not on healthy cells, it has succeeded in developing a powerful pipeline of cancer therapeutics, its cells destroy tumors and metastases that are invisible to the cell killing (cytolytic) consequences of more conventional T cell-based immunotherapies, enabling the therapist to detect cancer at early stages and to treat cancer cells before they progress into advanced stages.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • Care of Multhoff
  • 81675 Munich
  • Germany
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Care of Multhoff
  • 81675 Munich
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

multimmune Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore multimmune‘s full profile, request access.

Request a free trial

multimmune Patents

multimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3675877-A1 Hsp70 based combination therapy Pending 31-Aug-2017
US-12053505-B2 Hsp70 based combination therapy Active 31-Aug-2017
US-20200237860-A1 Hsp70 based combination therapy Active 31-Aug-2017
WO-2019043170-A1 Hsp70 based combination therapy Inactive 31-Aug-2017
EP-3250930-A1 Quantitative assay for heat shock protein 70 (hsp70) protein in body fluids Pending 27-Jan-2015 G01N33/57585
To view multimmune’s complete patent history, request access »

multimmune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

multimmune Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore multimmune‘s full profile, request access.

Request a free trial

multimmune FAQs

  • When was multimmune founded?

    multimmune was founded in 1999.

  • Where is multimmune headquartered?

    multimmune is headquartered in Munich, Germany.

  • What is the size of multimmune?

    multimmune has 3 total employees.

  • What industry is multimmune in?

    multimmune’s primary industry is Drug Discovery.

  • Is multimmune a private or public company?

    multimmune is a Private company.

  • What is multimmune’s current revenue?

    The current revenue for multimmune is .

  • Who are multimmune’s investors?

    Bayern Kapital and Sobera Capital have invested in multimmune.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process